Zenas BioPharmaZBIO stock score: 31/100
$25.04 · -5.22% · Scored Nov 19, 2026
- Technical
- 32
- Fundamental
- 31
- News
- —
The reading
Zenas BioPharma (ZBIO) scores 31 out of 100, which reads bearish, higher than 5% of Healthcare stocks and 7% of the 4,118 US stocks we score.
The composite weights fundamentals 80% and technicals 20%: fundamentals read 31, technicals 32.
Among the fundamentals, Quick Ratio at 100 and Price Target at 100 score highest, while Earnings Profitability (Quarterly) at 0 weighs the most against it.
On the daily chart, trend-following indicators average 24 and contrarian oscillators 61 — a split worth reading before trusting the technical total.
Since Aug 23, 2026 the composite has ranged from 31 to 52, and it is down 21 points over the period.
About Zenas BioPharma
Zenas BioPharma (ZBIO) is a biotechnology company that develops treatments for autoimmune diseases. Its lead candidate, obexelimab, is an antibody that binds two proteins on B cells, CD19 and FcγRIIb, to calm the activity of these immune cells without destroying them. In a Phase three trial in IgG4-related disease, a chronic fibro-inflammatory condition that damages organs, obexelimab reduced the risk of disease flares, and Zenas has submitted it for approval in the United States and Europe. Obexelimab is also being studied in systemic lupus erythematosus and relapsing multiple sclerosis. Zenas is developing orelabrutinib, an oral BTK inhibitor licensed from InnoCare Pharma, in Phase three trials for progressive forms of multiple sclerosis. Bristol Myers Squibb holds rights to obexelimab in Japan. Zenas has no approved products and funds its work with cash raised from investors and partnership payments.
In IgG4-related disease, Zenas faces competition from Amgen’s Uplizna and from steroids and other immune therapies, while in multiple sclerosis it competes with Roche, Sanofi and Novartis. Its edge rests on obexelimab’s approach of inhibiting B cells rather than depleting them, convenient self-injection and a pipeline that targets several large autoimmune diseases. Investors who follow ZBIO stock tend to watch the outcome of regulatory reviews for obexelimab and preparations for a commercial launch. Results from lupus and multiple sclerosis trials are closely followed. Cash runway, partnerships and spending on Phase three trials are other factors.
What’s driving the score
The strongest and weakest of the scorers that count toward ZBIO’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.
Fundamental
31Pulling it up
- Quick Ratio100
Quick ratio measures a company's ability to meet short-term obligations with liquid assets.
- Price Target100
Price target score compares the current stock price to analyst consensus targets.
Current assets divided by current liabilities: the ability to pay short-term bills.
Holding it back
Earnings Profitability (Quarterly) measures recent profitability using trailing 12-month quarterly data.
How reliably yearly earnings grow: the share of years with higher earnings, the compound growth rate, how steady that growth is, and the last two yearly changes.
Absolute profitability: whether the company is profitable, its net margin against the sector range, and how consistently it has been profitable over three years.
36 weighted scorers; 3 had no data today and are left out rather than counted as zero.
Technical · daily
28Pulling it up
Bollinger Bands (20-period) plot standard deviations above and below a moving average.
Bollinger Bands (50-period) measure where price sits between bands two standard deviations around its 50-period average.
Williams %R (7-period) places the close within the last 7 periods' high-low range.
Holding it back
Candlestick patterns recognize specific price formations that historically suggest continuation or reversal.
- VWAP0
Volume Weighted Average Price (VWAP) shows the average price weighted by volume.
Ichimoku Cloud is a comprehensive indicator showing support/resistance, trend direction, and momentum.
62 weighted scorers; 3 had no data today and are left out rather than counted as zero.
Technical score by timeframe
| Chart | Score | Weight |
|---|---|---|
| Hourly | 28 | 1 |
| Daily | 28 | 3 |
| Weekly | 40 | 2 |
Composite score, last 90 days
Show the daily numbers
| Date | Composite |
|---|---|
| Nov 19, 2026 | 31 |
| Nov 18, 2026 | 33 |
| Nov 17, 2026 | 35 |
| Nov 16, 2026 | 34 |
| Nov 15, 2026 | 34 |
| Nov 14, 2026 | 34 |
| Nov 13, 2026 | 34 |
| Nov 12, 2026 | 32 |
| Nov 11, 2026 | 46 |
| Nov 10, 2026 | 46 |
| Nov 8, 2026 | 43 |
| Nov 7, 2026 | 43 |
| Nov 6, 2026 | 43 |
| Nov 5, 2026 | 40 |
| Nov 4, 2026 | 47 |
| Nov 3, 2026 | 46 |
| Nov 2, 2026 | 45 |
| Nov 1, 2026 | 45 |
| Oct 30, 2026 | 45 |
| Oct 29, 2026 | 47 |
| Oct 28, 2026 | 46 |
| Oct 27, 2026 | 44 |
| Oct 26, 2026 | 44 |
| Oct 25, 2026 | 43 |
| Oct 24, 2026 | 43 |
| Oct 23, 2026 | 44 |
| Oct 22, 2026 | 46 |
| Oct 21, 2026 | 47 |
| Oct 20, 2026 | 46 |
| Oct 19, 2026 | 43 |
| Oct 18, 2026 | 40 |
| Oct 17, 2026 | 40 |
| Oct 16, 2026 | 41 |
| Oct 15, 2026 | 41 |
| Oct 14, 2026 | 40 |
| Oct 13, 2026 | 40 |
| Oct 12, 2026 | 42 |
| Oct 11, 2026 | 43 |
| Oct 10, 2026 | 43 |
| Oct 9, 2026 | 43 |
| Oct 8, 2026 | 42 |
| Oct 7, 2026 | 45 |
| Oct 6, 2026 | 44 |
| Oct 5, 2026 | 46 |
| Oct 4, 2026 | 46 |
| Oct 3, 2026 | 48 |
| Oct 2, 2026 | 46 |
| Oct 1, 2026 | 46 |
| Sep 30, 2026 | 44 |
| Sep 29, 2026 | 44 |
| Sep 28, 2026 | 45 |
| Sep 27, 2026 | 44 |
| Sep 26, 2026 | 44 |
| Sep 25, 2026 | 44 |
| Sep 24, 2026 | 46 |
| Sep 23, 2026 | 49 |
| Sep 22, 2026 | 51 |
| Sep 21, 2026 | 50 |
| Sep 20, 2026 | 48 |
| Sep 19, 2026 | 48 |
| Sep 18, 2026 | 48 |
| Sep 17, 2026 | 49 |
| Sep 16, 2026 | 50 |
| Sep 15, 2026 | 49 |
| Sep 14, 2026 | 49 |
| Sep 13, 2026 | 48 |
| Sep 12, 2026 | 48 |
| Sep 11, 2026 | 48 |
| Sep 10, 2026 | 47 |
| Sep 9, 2026 | 49 |
| Sep 8, 2026 | 51 |
| Sep 7, 2026 | 50 |
| Sep 6, 2026 | 51 |
| Sep 5, 2026 | 51 |
| Sep 4, 2026 | 50 |
| Sep 3, 2026 | 51 |
| Sep 2, 2026 | 51 |
| Sep 1, 2026 | 50 |
| Aug 31, 2026 | 50 |
| Aug 30, 2026 | 49 |
| Aug 29, 2026 | 49 |
| Aug 28, 2026 | 49 |
| Aug 27, 2026 | 51 |
| Aug 26, 2026 | 51 |
| Aug 25, 2026 | 51 |
| Aug 24, 2026 | 50 |
| Aug 23, 2026 | 52 |
Key facts
- Market cap
- $1.7B
- Sector
- Healthcare
- Industry
- Biotechnology
- Beta
- -0.86
- Risk grade (1–10)
- 7
- Next earnings
- Nov 5, 2026
Biotechnology peers
| Company | Market cap | Score |
|---|---|---|
| MAZE Maze Therapeutics | $1.8B | 34 |
| STOK Stoke Therapeutics | $1.8B | 52 |
| RARE Ultragenyx Pharmaceutical | $1.8B | 47 |
| AGIO Agios Pharmaceuticals | $1.7B | 47 |
| RXRX Recursion Pharmaceuticals | $1.7B | 45 |
| VIR Vir Biotechnology | $1.7B | 54 |
Questions
What is ZBIO's stock rating today?
ZBIO scores 31/100 (Bearish) as of Nov 19, 2026: technical 32, fundamental 31. Scores are recomputed every night.
What does Zenas BioPharma do?
Zenas BioPharma (ZBIO) is a biotechnology company that develops treatments for autoimmune diseases. Its lead candidate, obexelimab, is an antibody that binds two proteins on B cells, CD19 and FcγRIIb, to calm the activity of these immune cells without destroying them.
Is ZBIO stock a buy?
The score is not a buy or sell recommendation. A 31 says the technical and fundamental signals we measure lean bearish today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.
How is the ZBIO score calculated?
98 weighted scorers feed it today: 36 fundamental, scored against Healthcare ranges, and 62 technical on the daily chart, with 3 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.
Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.
Embed this score
A badge for a blog post, newsletter or README. It updates every night and links back here. More badges
HTML
<a href="https://stocksscores.com/stocks/zbio/"><img src="https://stocksscores.com/stocks/zbio/badge.svg" alt="ZBIO stock score" height="20"></a>
Markdown
[](https://stocksscores.com/stocks/zbio/)